Boehringer Ingelheim
Aug 31, 2016
BI & Duke Clinical Research Institute have expansion; BioInvent Inks Mfg. Pact; Elite Pharma, SunGen Pharma in Development & License Deal; Boehringer and Saniona Develop new Compounds; BioLineRx and I-Bridge Capital Establish; Alliance between Harvard and Tata Companies; Innovative Targeting Solutions and Johnson & Johnson Innovation collaborate
Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute have expanded their collaboration to create the largest patient registry for Idiopathic Pulmonary Fibrosis (IPF) The IPF-PRO Registry will be widened to cover 1500 patients spread over 45 clinical sites which will stimulate understand...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
